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Abstract
Background: Numerous epidemiological studies have evaluated the association between the CDH1 -160C/A
polymorphism and the risk of breast cancers. However, these studies have yielded conflicting results. To derive a
more precise estimation of this association, this meta-analysis was conducted.
Methods: A comprehensive search using the keywords “CDH1,” “E-Cadherin,” “polymorphism,” “SNP,” and “variant”
combined with “breast,” “cancer,” “tumor,” or “carcinomas” was conducted. Pooled odds ratios (ORs) with 95 %
confidence intervals (CIs) were appropriately calculated using a fixed effect or random effect model. Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2009 checklist was used for this meta-analysis.
Results: Four publications including five studies were identified. It was found that the CDH1 -160C/A polymorphism
was significantly associated with breast cancer risk in the dominant model (CA + AA vs. CC: OR = 1.207, 95 % CI = 1.
031–1.412, P = 0.019).
Conclusions: Our meta-analysis demonstrated that the -160C/A polymorphism in the CDH1 gene might contribute to
breast cancer susceptibility. Further investigations using a much larger sample including different ethnicities are still
needed to verify this association.
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Background
E-cadherin (CDH1), located on chromosome 16q22.1, is
one of the most important tumor suppressor genes en-
coding an adhesion glycoprotein [1, 2]. Studies showed
that CDH1 plays a critical role in intercellular adhesion,
cell polarity, cell signaling, and maintenance of normal
tissue morphology and cellular differentiation, which is
expressed in almost all epithelial cells [3–5]. E-cadherin
expression loss has been described in gynecological neo-
plasias, and CDH1 silencing by promoter methylation
has been detected in both cervical and endometrial tu-
mors [6, 7].
Several polymorphisms have been identified within the
CDH1 gene, and emerging numbers of studies show that
genetic variations within the E-cadherin gene are involved
in oncogenesis and development [8–11]. The -160C/A
(rs16260) is an important functional SNP located in the
promoter region that has significant effects on transcrip-
tional activity in transient transfection studies [8–10]. Pre-
vious studies have indicated the association of the -160C/
A polymorphism with the risk and progression of various
human cancers [4]. However, the polymorphism’s genetic
effects vary in different cancer types. Recent epidemiologic
studies revealed an increased cancer risk for the A (-160)
allele carriers [12–15] and a protective role in gastric can-
cer [16], while the others showed no significant associ-
ation [17–21]. Researchers report inconsistent breast
cancer results; some studies found no association
among -160A allele carriers [17, 22], while others found a
significantly increased risk [23]. Cattaneo et al. found A
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allele carriers significantly increased risk for endometrial
cancer [24] but not for cervical and ovarian cancer [24, 25].
Thus, these observations raised a controversial question
regarding the significance of -160C/A in cancer patho-
genesis, especially in breast cancer. Obviously, an indi-
vidual study’s statistical power could be very limited for
efficient assessment of the -160A allele. Integration of
these data sets may provide improved statistical power
to detect the significance.
Methods
Publication selection
Studies examining the association between the
CDH1 -160C/A polymorphism and breast cancer
were systematically searched using the following key
words: “CDH1,” “E-Cadherin,” “polymorphism,” “SNP,”
and “variant” combined with “breast,” “cancer,” “tumor,” or
“carcinomas,” and the studies were identified via an elec-
tronic search on PubMed, Elsevier, Springer, Wiley,
EBSCO, OVID, and Google scholar. Publication titles and
abstracts were carefully reviewed. We also manually
searched and verified the references of those retrieved arti-
cles to obtain other relevant publications. The last search
included results up to July 2014.
Inclusion and exclusion criteria
Studies for further meta-analysis were selected based on
the following criteria: (1) original epidemiological studies
on the association between the CDH1 promoter poly-
morphsim and breast cancer patients; (2) case-control
studies; (3) studies containing at least two comparison
groups (cancer group vs. control group); or (4) detailed
genotyping data. For duplicated studies, only those with
the largest sample size in our present study were included.
The following criteria to exclude studies were used: (1)
studies from which genotype frequencies or alleles could
not be obtained; (2) studies on family members; (3) sys-
tematic reviews or abstracts; (4) animal studies; (5) non-
English language; and (6) <50 cases.
Data extraction
Data were extracted from all eligible studies by two in-
dependent reviewers. Discrepancies were resolved by
consulting with a third reviewer or the authors’ discus-
sion. For each eligible study, publication details were
collected based on the following aspects: name of the
first author, year of publication, country of origin, cancer
type, sources of control and case groups, genotyping
methods for SNP, and the frequency of the genotypes
and alleles of the CDH1 -160C/A polymorphism in cases
and controls. For studies including subjects of different
ethnic groups, data were extracted separately for each
ethnic group whenever possible. Finally, PRISMA 2009
checklist (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses: The PRISMA Statement. PLoS
Med 6(6): e1000097. doi:10.1371/journal.pmed1000097)
was used for this meta-analysis.
Statistical analysis
The wild type CC genotype of CDH1 -160C/A SNP was
considered as a reference. Pooled effects were calculated
for the codominant model (AA vs. CC; CA vs. CC), dom-
inant model (CA +AA vs. CC), and recessive model (AA
vs. CC +CA). The Hardy-Weinberg equilibrium (HWE)
for each study’s control group was assessed using the
goodness-of-fit test (χ2 or Fisher’s exact test).
The heterogeneity among included studies was evalu-
ated using the Cochran’s Q-test and Higgins’ I2 statistic.
Heterogeneity was defined as low when P ≥ 0.1, according
to the Cochran’s Q-test, or when I2 was less than 50 %, ac-
cording to the Higgins’ I2 statistic. A fixed effect model
was then applied using the Mantel-Haenszel method.
Otherwise, we applied a random effect model using the
DerSimonian and Laird method. A pooled odds ratio
(OR) with 95 % CI was used to assess the strength of asso-
ciation between the CDH1 -160C/A SNP polymorphism
and cancer risk, depending on the heterogeneity of the
analysis. A sensitivity analysis was performed to evaluate
how robust the pooled effect size was at removing the ef-
fects of individual studies. An individual study was sus-
pected to have excessive influence if the point estimate
was outside the 95 % CI of the combined effect size after
it was removed from the analysis. The potential publica-
tion bias among the included studies was assessed using
the Egger test and Begg test. Statistical analysis was per-
formed using STATA 11.0 software (Stata Corporation,
College Station, TX, USA). All P values were two-sided,
with P < 0.05 considered statistically significant.
Results
Literature screening and study selection
After a preliminary on-line search, 64 potentially relevant
articles were identified for further detailed evaluation.
Twenty-four articles were selected for full-text review after
40 were excluded by manually screening the titles, ab-
stracts, and key words for review articles, laboratory stud-
ies, reduplicated reports, non-English contributions, or
those irrelevant to the current analysis. Finally, there were
only four papers [17, 23, 24, 26] including five studies
(1344 cases and 1569 controls involved) in the pooled ana-
lyses (Fig. 1) after 20 studies were excluded because they
contained no extractable data, other polymorphism data,
or review. Additionally, a list of excluded studies and rea-
sons for exclusions was also provided in Additional file 1.
Study characteristics
The main characteristics and basic information of eli-
gible studies are summarized in Table 1. The studies
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enrolled 1344 patients from Switzerland, the Czech
Republic, Italy, China, and India. Multiple genotyping
methods were performed in the studies, including
PCR-RFLP, PCR-SSCP, TaqMan PCR, and DNA sequen-
cing. The distribution of genotypes in the controls of all
studies was consistent with Hardy-Weinberg equilibrium,
except in one study [26]. Then, the association between
CDH1 -160C/A SNP and breast cancer risk was analyzed.
Heterogeneity tests
The genotype data for breast cancer in the two studies
were homogenous for the codominant genetic model
(CA vs. CC: Q-test = 1.55, P = 0.818, I2 = 0.0 %) and the
dominant genetic model (CA + AA vs. CC: Q-test = 2.95,
P = 0.566, I2 = 0.0 %) (Table 2), and the fixed-effects
model in these studies was employed. However, hetero-
geneity was significant for the codominant genetic model
(AA vs. CC: Q-test = 8.41, P = 0.078, I2 = 52.5 %) and the
recessive genetic model (AA vs. CC + CA: Q-test = 10.54,
P = 0.032, I2 = 62.0 %) and allele comparison (A vs. C: Q-
test = 11.20, P = 0.024, I2 = 64.3 %), and a random-effects
model was performed.
Quantitative data synthesis
In the present study, the relationship between the
CDH1 -160C/A polymorphism and breast cancer risk was
Fig. 1 Flow chart of literature search and selection according to inclusion and exclusion criteria
Table 1 CDH1 -160C/A SNP genotype distribution in cases and controls
Author-year Country Cancer
type
Method Genotype (N) P HWE
controlsCase Control
CC CA AA CC CA AA
Lei et al. 2002 Swiss Breast PCR-SSCP 226 166 32 135 92 21 0.350
Lei et al. 2002 Czech Breast PCR-SSCP 74 60 18 51 42 7 0.677
Cattaneo et al. 2006 Italy Breast PCR-RFLP 50 43 6 139 89 18 0.476
Yu et al. 2006 China Breast Taqman 222 201 44 243 187 39 0.721
Tipirisetti et al. 2013 India Breast Sequencing 120 26 56 175 42 33 <0.001
PCR-SSCP Polymerase chain reaction single-strand conformation polymorphism, RFLP restriction fragment length polymorphism
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analyzed. The results revealed significant associations be-
tween the CDH1 -160C/A polymorphism and breast cancer
in the dominant model (CA +AA vs. CC: OR = 1.207,
95 % CI = 1.031–1.412, P = 0.019) but not in the other four
genotype distributions (A vs. C: OR = 1.231, 95 % CI =
0.992–1.528, P = 0.060; AA vs. CC: OR = 1.397, 95 % CI =
0.922–2.116, P = 0.115; CA vs. CC: OR = 1.116, 95 %
CI = 0.941–1.325, P = 0.208; AA vs. CC +CA: OR = 1.338,
95 % CI = 0.850–2.105, P = 0.208) (Fig. 2, Table 2).
Sensitivity analysis
To further reinforce our conclusions, a sensitivity analysis
was conducted to assess the results’ stability by sequentially
omitting each eligible study. The results showed that no
other single study influenced the pooled ORs significantly,
indicating that our results were statistically robust (detailed
data not shown) (Fig. 3).
Publication bias
The studies’ publication biases were assessed using the
Begg and Egger tests. The Egger weighted regression
method indicated no evidence of publication bias for all
genetic models (A vs. C: P = 0.687; AA vs. CC: P = 0.680;
CA vs. CC: P = 0.492; AA + CA vs. CC: P = 0.692; AA vs.
CC + CA: P = 0.698) (Table 3). This result was confirmed
using the Begg rank correlation method (A vs. C: P =
0.462; AA vs. CC: P = 0.806; CA vs. CC: P = 0.221; AA +
CA vs. CC: P = 1.000; AA vs. CC + CA: P = 0.806)
(Table 3). Hence, there was no obvious publication bias
revealed in the current meta-analysis.
Discussion
As a tumor suppressor, E-cadherin expression is fre-
quently reduced or lost in epithelial tumors [3, 5]. This
leads to the suboptimal regulation of cell-cell adhesion,
loss of cellular polarity, tissue disorganization, tumor
progression, and metastasis [3, 4]. Essentially, E-cadherin
Table 2 Meta-analysis of the association between CDH1 -160C/A






P value Heterogeneity Effects
modelI2 (%) P value
A vs C 1.231 0.992–1.528 0.060 64.3 0.024 Random
AA vs CC 1.397 0.922–2.116 0.115 52.5 0.078 Random
CA vs CC 1.116 0.941–1.325 0.208 0.0 0.818 Fixed
CA + AA vs CC 1.207 1.031–1.412 0.019 0.0 0.566 Fixed
AA vs CC + CA 1.338 0.850–2.105 0.208 62.0 0.032 Random
Fig. 2 Forest plots of effect estimates for CDH1 -160 C/A polymorphism in different genetic models. For each of the studies, the boxes and
horizontal lines represent the OR and the corresponding 95 % CI; the area of the boxes indicates the weight (inverse of the variance). The diamond
corresponds to the summary OR and 95 % CI
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is the main adhesion molecule of epithelia, its reduced
expression being implicated in the epithelial carcino-
genic process. Researchers have reported several functional
polymorphisms that diminish E-cadherin expression
[8–10, 24], among which -160C/A SNP showed tran-
scriptional regulation of the CDH1 gene in different
epithelial cell types.
Cattaneo et al. revealed that -160C/A SNP within the
CDH1 promoter region is a functional polymorphism
that affects transcription efficiency in vitro [24]. By transi-
ent transfection experiments, A allele activity was reduced
by 54 and 67 % compared to the -160C allele in cervical
and in colon cancer cells, respectively [24]. Therefore,
the -160A CDH1 promoter variant, associated with reduced
gene expression, may be regarded as a possible low pene-
trance susceptibility allele for epithelial tumors. However,
studies about the relation between CDH1 -160C/A poly-
morphism were various. CDH1 -160A allele carriers have a
significantly elevated risk for endometrial cancer [24] but
not for cervical cancer and ovarian cancer [24, 25]. Thus,
we were interested in resolving the controversial question
regarding the significance of CDH1 -160C/A in breast can-
cer pathogenesis. On this basis, the present meta-analysis
study focused on breast cancer.
After critically reviewing the five studies on the
CDH1 -160C/A polymorphism (1344 cases total, 1569
control), we performed a comprehensive assessment to in-
vestigate the significance of CDH1 -160C/A in breast
Fig. 3 Sensitivity analysis by omitting each study to reflect the influence of each study on pooled OR in different genetic models
Table 3 Publication bias test for CDH1 -160C/A polymorphism
Comparisons Egger test Begg test
Coefficient P value 95 % CI P value
A vs C 1.482 0.687 −9.153–12.118 0.462
AA vs CC −1.157 0.680 −9.239–6.925 0.806
CA vs CC −0.807 0.492 −4.098 0.221
AA + CA vs CC 0.754 0.692 −4.743–6.250 1.000
AA vs CC + CA −1.218 0.698 −10.29–7.852 0.806
Ma et al. World Journal of Surgical Oncology  (2016) 14:169 Page 5 of 7
cancer pathogenesis. The results implied a conspicuously
significant relationship between the CDH1 -160C/A poly-
morphism and breast cancer risk under the dominant
genetic model (AA + CA vs. CC, OR = 1.207, P = 0.019).
These results indicated that the -160 AA genotype in-
creased breast cancer risk, which was consistent with re-
sults on other cancer types, such as prostate, urothelial,
and bladder cancers [27–29]. However, the results were
inconsistent with results on colorectal cancer (CRC)
[12, 30], which showed that CDH1 -160C/A polymor-
phisms could reduce CRC risk. These results revealed that
the CDH1 -160C/A polymorphism might have different
effects on distinct cancers, and this discrepancy may result
from different carcinogenesis mechanisms, such as genetic
background, environment exposure, dietary habit, race, or
family history.
Concerning breast cancer, Yu et al. found that -160A
carriers were 30 % more likely to be breast cancer cases
than women with -160C carriers [23]. Conversely, Lei et al.
genotyped the -160C/A SNP among 576 cases and 348
controls and found no association with breast cancer risk
[17]. Our present study revealed that -160A significantly
increased breast cancer risk (CA +AA vs CC, OR = 1.207,
P = 0.019), which is in good agreement with previous ob-
servations on other population samples [17, 31]. However,
we enrolled only five studies in the present study. Well-
designed, unbiased, and large case-control studies should
be performed to acquire a more precise association be-
tween the CDH1 -160C/A polymorphism and cancer risk.
As no significant publication bias was revealed in our
meta-analysis, sensitivity analysis also revealed that our
results were statistically robust. Thus, the results for the
association assessed in the present study are relatively
convincing since we used a rigorous analytic approach.
However, there are still a number of limitations in this
meta-analysis.
Firstly, while we identified no publication bias, there is
still a possibility that our meta-analysis was biased to-
ward a positive result, since negative results were likely
to be unreported. Secondly, our controls were not uni-
formly defined. Although the healthy population was the
main control source, some might be patients with even
benign tumors. Thirdly, other factors influencing car-
cinogenesis should be considered, such as genetic back-
ground and environmental and lifestyle factors. Finally,
our results had to be interpreted with caution due to un-
adjusted estimates, so further studies should be con-
ducted to confirm our unadjusted estimates.
Conclusions
In conclusion, these data provided further evidence that
the CDH1 -160C/A polymorphism may represent a risk
factor for breast cancer development. Further investiga-
tions using a much larger sample, with interactions
between the environment and genes taken into account,
are still needed to elucidate the findings in this meta-
analysis.
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